Lonza has bolstered its presence in the field of antibody-drug conjugates (ADC) by extending its manufacturing collaboration with a renowned biopharma company. This strategic move involves the expansion of its bioconjugation operations at the Ibex Biopark located in Visp, Switzerland. Under this
The biopharmaceutical industry has seen significant advancements, particularly in the production of monoclonal antibodies (mAbs), which offer personalized therapies for a range of chronic and debilitating conditions. Despite these advancements, manufacturers face growing pressure to expedite the
Rentschler Biopharma, a globally recognized Contract Development and Manufacturing Organization (CDMO), is making significant strides in the biomanufacturing landscape. The company's recent investments showcase its commitment to expanding cGMP capabilities and bolstering cell and gene therapy
The biopharmaceutical industry is undergoing a significant transformation, driven by the need for speed, safety, and cost-efficiency in therapeutic production. The advent of new modalities like cell and gene therapies has added layers of complexity to the already intricate production pipelines. As
The biopharma sector is facing a significant wave of layoffs in 2024, affecting thousands of employees across various companies. This trend is shaped by numerous internal and external factors, including corporate restructuring, market adaptations, strategic divestments, and cost-saving measures.
The biopharmaceutical manufacturing sector stands at the brink of a revolution, driven by the relentless pursuit of speed, safety, and scalability. The emergence of new therapeutic modalities, coupled with the increasing demand for rapid and cost-effective production solutions, has necessitated a
